Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Health Care Stocks Explained: Why You Might Want to Invest
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to Calculate Stock Profit
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- With Risk Tolerance, One Size Does Not Fit All
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20240125142140&h=45&w=95&zc=2){kind=logo}
